Ali Alhijji

Dr. Ali Alhijji

internal medicine, King Saud University, College of Medicine, Riyadh, Ar Riyāḑ, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2022 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
Mazin BarryMazin Barry
Mazin Barry
SAShahad Abdulrahman AlShehri
Shahad Abdulrahman AlShehri
AAAhlam Alguhani
Ahlam Alguhani
MBMohammad Barry
Mohammad Barry
Ali AlhijjiAli Alhijji
Ali Alhijji
TMTaim Abdullah Muayqil
Taim Abdullah Muayqil
Background: Disseminated nocardiosis still causes significant morbidity and mortality and is often caused by Nocardia asteroides, N. basiliensis, and N. farcinica and are often treated with trimethoprim–sulfamethoxazole (TMP–SMX). Nocardia otitidiscaviarum (N. otitidiscaviarum) rarely causes disseminated disease and resistance to TMP–SMX is even more rare. Case presentation: A 37-year-old woman with metastatic breast cancer and right ear deafness with recent occupational gardening and manipulating soil, presented to the hospital with first time seizure and multiple skin nodules. Magnetic resonance imaging (MRI) showed ring enhancing lesions, biopsy of the skin and brain lesions grew N. otitidiscaviarum. She was empirically treated with TMP–SMX and Imipenem–Cilastatin, however, almost three weeks into therapy, susceptibility results revealed it to be resistant to both antimicrobials, she was subsequently changed to Amikacin, Linezolid, Moxifloxacin, and Doxycycline but ultimately died. Conclusions: This case report highlights the importance of suspecting a rare Nocardia species in patients at risk with proper occupational exposure, moreover, TMP–SMX resistance should be suspected with lack of clinical response, this may have important implications on clinical practice when facing similar infections.

1 April 2020 in Journal of Infection and Public Health
Verified
Journal Article
Open access
MAMajed Alghoribi
Majed Alghoribi
KBKhalifa Binkhamis
Khalifa Binkhamis
AAAbdulrahman Alswaji
Abdulrahman Alswaji
Ali AlhijjiAli Alhijji
Ali Alhijji
AAAynaa Alsharidi
Aynaa Alsharidi
ASAli Somily
Ali Somily
Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae have been isolated from human patients in many countries across the globe but rarely in Saudi Arabia. Here we provide the genomic characterization of the first KPC-producing K. pneumoniae isolated from the urine of a patient in Riyadh, Saudi Arabia, who had a recent travel history to Egypt involving a medical procedure. Presence of KPC-encoding gene initially detected with the Xpert Carba-R assay was confirmed by traditional PCR. Susceptibility testing using the VITEK 2 system, E-test and microbroth dilution methods showed that the K. pneumoniae isolate, namely SA01_KPC-2, was resistant to all antibiotics except colistin and ceftazidime/avibactam. Whole-genome sequencing (WGS), performed on the Illumina Miseq instrument, identified the isolate as sequence type (ST) 383 and serotype KL30-D1 O1v2. Genome assembly of SA01_KPC-2 indicated the presence of two plasmids. Plasmid pSA01_KPC-2, of approximately 45.9 kb in size, harbored the blaKPC-2 flanked by ISKpn27 and ISKpn6 and had a backbone similar to published KPC-carrying IncX6 plasmids. The second plasmid pSA01_incHIB1, a derivative of published 372-kb plasmid pKpvST383, carried genes encoding virulence factors and resistance to five classes of antibiotics. The isolation of the first KPC producer in Saudi Arabia requires high attention and rapid interventions to prevent further spread.

1 May 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
Mazin BarryMazin Barry
Mazin Barry
NANouf A Althabit
Nouf A Althabit
LALayan Akkielah
Layan Akkielah
AAAbdulellah Almohaya
Abdulellah Almohaya
MAMuath Alotaibi
Muath Alotaibi
AAAbdulkarim Alhetheel
Abdulkarim Alhetheel
To describe the clinical characteristics and outcomes of hospitalized COVID-19 patients in a MERS-CoV referral hospital during the peak months of the pandemic. A single-center case series of hospitalized individuals with confirmed SARS-CoV-2 infections in King Saud University Medical City (KSUMC), an academic tertiary care hospital in Riyadh, KSA. Clinical and biochemical markers were documented. Risks for ventilatory support, intensive care unit (ICU) admission, and death are presented. Out of 12,688 individuals tested for SARS-CoV-2 by RT-PCR, 2,683 (21%) were positive for COVID-19. Of the latter, 605 (22%) patients required hospitalization with a median age of 55 years, and 368 (61%) were male. The most common comorbidities were hypertension (43%) and diabetes (42%). Most patients presented with fever (66%), dyspnea (65%), cough (61%), elevated IL-6 (93.5%), D-dimer (90.1%), CRP (86.1%), and lymphopenia (41.7%). No MERS-CoV co-infection was detected. Overall 91 patients (15%) died, risk factors associated with mortality were age of 65 years or older OR 2.29 [CI 1.43–3.67], presence of two or more comorbidities OR 3.17 [CI 2.00–5.02], symptoms duration of seven days or less OR 3.189 [CI (1.64 – 6.19]) lymphopenia OR 3.388 [CI 2.10–5.44], high CRP OR 2.85 [CI 1.1–7.32], high AST OR 2.95 [CI 1.77–4.90], high creatinine OR 3.71 [CI 2.30–5.99], and high troponin-I OR 2.84 [CI 1.33–6.05]. There is a significant increase in severe cases of COVID-19. Mortality was associated with older age, shorter symptom duration, high CRP, low lymphocyte count, and end-organ damage.

1 October 2021 in Journal of Infection and Public Health
Verified
Journal Article
Open access
Mazin BarryMazin Barry
Mazin Barry
MAMuath Alotaibi
Muath Alotaibi
AAAbdulellah Almohaya
Abdulellah Almohaya
AAAbdulwahab Aldrees
Abdulwahab Aldrees
Ali AlhijjiAli Alhijji
Ali Alhijji
JAJaffar A. Al-Tawfiq
Jaffar A. Al-Tawfiq
Coronavirus disease 2019 (COVID-19) has resulted in millions of deaths, including more than 6000 deaths in the Kingdom of Saudi Arabia (KSA). Identifying key predictors of intensive care unit (ICU) admission and mortality among infected cases would help in identifying individuals at risk to optimize their care. We aimed to determine factors of poor outcomes in hospitalized patients with COVID-19 in a large academic hospital in Riyadh, KSA that serves as a Middle East Respiratory Syndrome coronavirus (MERS-CoV) referral center. This is a single-center retrospective cohort study of hospitalized patients between March 15 and August 31, 2020. The study was conducted at King Saud University Medical City (KSUMC). COVID-19 infection was confirmed using real-time reverse transcriptase polymerase chain reaction (RT-PCR) for SARS-COV-2. Demographic data, clinical characteristics, laboratory, radiological features, and length of hospital stay were obtained. Poor outcomes were, admission to ICU, need for invasive mechanical ventilation (IMV), and in-hospital all-cause mortality. Out of 16,947 individuals tested in KSUMC, 3480 (20.5%) tested positive for SARS-CoV-2 and of those 743 patients (21%) were hospitalized. There were 62% males, 77% were younger than 65 years. Of all cases, 204 patients (28%) required ICU admission, 104 (14%) required IMV, and 117 (16%) died in hospital. In bivariate analysis, multiple factors were associated with mortality among COVID-19 patients. Further multivariate analysis revealed the following factors were associated with mortality: respiratory rate more than 24/min and systolic blood pressure <90 mmHg in the first 24 h of presentation, lymphocyte count 37 units/L in the first 48 h of presentation, while a RT-PCR cycle threshold (Ct) value ≤24 was a predictor for IMV. Variable factors were identified as predictors of different outcomes among COVID-19 patients. The only predictor of IMV was a low initial Ct values of SARS-CoV-2 PCR. The presence of tachypnea, hypotension, lymphopenia, and elevated AST in the first 48 h of presentation were independently associated with mortality. This study provides possible independent predictors of mortality and invasive mechanical ventilation. The data may be helpful in the early identification of high-risk COVID-19 patients in areas endemic with MERS-CoV.

1 March 2024 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
SASaad Alsaleh
Saad Alsaleh
AAAhmed Alhussien
Ahmed Alhussien
AAAbduljabbar Alyamani
Abduljabbar Alyamani
FAFahad Alhussain
Fahad Alhussain
Ali AlhijjiAli Alhijji
Ali Alhijji
FAFatimah Saad Alshahrani
Fatimah Saad Alshahrani
Objectives/Hypothesis: To assess the efficacy of 0.23% povidone-iodine (PVP-I) nasal rinses and mouth washes on detectability of the coronavirus disease 2019 (COVID-19) virus and cycle threshold (Ct) values in nasopharyngeal swabs. Study design: This was an open-label, prospective, randomized, placebo-controlled clinical trial. Setting: The study was conducted in King Saud University Medical City, Riyadh, Saudi Arabia, from August 2021 to July 2022. Methods: Participants diagnosed with SARS-CoV-2 were randomly assigned to one of three groups, with participants receiving either 0.23% PVP-I, 0.9% normal saline (NS) nasal rinses and mouth washes, or no intervention (control group). Nasopharyngeal swabs were taken 4, 8, 12, and 18 days after the first swab to measure the detectability of the virus and the Ct. Results: A total of 19 participants were involved in this study. The mean viral survival was 9.8, 12, and 12.6 days for the PVP-I, NS, and control groups, respectively, with a statistically significant difference (p = 0.046). The Ct mean values were 23 ± 3.4, 23.5 ± 6.3, and 26.3 ± 5.9 at the time of recruitment and 25.2 ± 3.5, 15 ± 11.7, and 26.9 ± 6.4 after 4 days for the PVP-I, NS, and control groups, respectively. Conclusions: When used continuously at a concentration of 0.23%, PVP-I showed promising results in terms of decreasing the pandemic burden by reducing the period of infectiousness and viral load. However, the use of PVP-I did not result in significantly different changes in the quality-of-life parameters in recently vaccinated and mild COVID-19 patients.

10 April 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
WAWajude Ahmed Alabdullatif
Wajude Ahmed Alabdullatif
AAAhmad Tayseer Almnaizel
Ahmad Tayseer Almnaizel
Ali AlhijjiAli Alhijji
Ali Alhijji
AAAldanah A. Alshathri
Aldanah A. Alshathri
AAAhmed Albarrag
Ahmed Albarrag
IBIman Bindayel
Iman Bindayel
Background: The Coronavirus Disease-19 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has been declared a worldwide pandemic. The severity of COVID-19 varies greatly across infected individuals. Possible factors may include plasma levels of 25(OH)D and vitamin D binding protein (DBP), as both are involved in the host immune response. Other possible nutrition-related factors include malnutrition and/or obesity which disrupt the optimal host immune response to infections. Current literature shows inconsistent evidence about the association of plasma 25(OH)D3 and DBP on infection severity and clinical outcomes. Objectives: This study aimed to measure plasma 25(OH)D3 and DBP in hospitalized COVID-19 cases and assess their correlation with infection severity, inflammatory markers, and clinical outcome. Methods: 167 patients were included in this analytical cross-sectional study, of which 81 were critical and 86 were non-critical hospitalized COVID-19 patients. Plasma levels of 25(OH)D3, DBP, and the inflammatory cytokines, IL-6, IL-8, IL-10, and TNF-α were assessed using the Enzyme-linked Immunosorbent Assay (ELISA). Information regarding biochemical and anthropometrical indices, hospital length of stay (LoS), and illness outcome was obtained from the medical records. Results: Plasma 25(OH)D3 level was found to be significantly lower in critical compared to non-critical patients (Median = 8.38 (IQR = 2.33) vs. 9.83 (IQR = 3.03) nmol/L, respectively; p < 0.001), and it positively correlated with hospital LoS. However, plasma 25(OH)D3 did not correlate with mortality or any of the inflammatory markers. DBP on the other hand correlated positively with mortality (rs = 0.188, p = 0.015) and hospital LoS (rs = 0.233, p = 0.002). DBP was significantly higher in critical than non-critical patients (Median = 1262.18 (IQR = 463.66) vs. 1153.35 (IQR = 418.46) ng/mL, respectively; p < 0.001). Furthermore, IL-6 and IL-8 were significantly higher in critical than non-critical patients. However, no differences were found in IL-10, TNF-α, IL-10/TNF-α, TNF-α/IL-10, IL-6/IL-10, or CRP between groups. Conclusion: The current study found that critical COVID-19 patients had lower 25(OH)D3 than non-critical patients, yet, levels were found to be suboptimal in both groups. Further, critical patients had higher DBP levels as compared to non-critical patients. This finding may encourage future research to unravel the effects of this understudied protein that appears to have significant associations with inflammation, even though the precise mechanism is unknown.